Based on our current operating plans, we are narrowing our guidance for the full year of 2024 as follows. Total revenue expected to be in the range of $145,000,000 to $155,000,000 as compared to previous guidance of $145,000,000 to $160,000,000 U. S. Exfoliov net product revenue expected to be in the range of $110,000,000 to $115,000,000 as compared to previous guidance of $105,000,000 to $120,000,000 R and D and SG and A expenses are expected to be in the range of $255,000,000 to $265,000,000 which includes approximately $20,000,000 of estimated non cash stock based compensation expense as compared to previous guidance of $250,000,000 to 265,000,000 dollars And finally, we expect our existing cash, cash equivalents and investments, the revenue we expect to generate from Xplovio net product sales and other license revenues and ongoing disciplined expense management and cost saving measures will be sufficient to fund our planned operations into Q1 2026. Note that our cash runway does not include paying off the remaining 2025 convertible notes and our $25,000,000 liquidity covenant under the new term loan.